Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19

Pathogens

卷:10

Elisabetta Fabbri¹  Michela Fantini¹  Marta Flachi²  Angelo Rigotti²  Giovanni Mosconi³  Alessandra Spazzoli³  Paolo Ferdinando Bruno³  Andrea Buscaroli⁴  Matteo Righini⁴  Gaetano La Manna⁵  Maria Cappuccilli⁵  Pasqua Schiavone⁶  Vittorio Sambri⁶  Simona Semprini⁶  Laura Grumiro⁶  Maria Michela Marino⁶ 

[1] Local Healthcare Authority of Romagna (AUSL Romagna), 48121 Ravenna, Italy;

[2] Nephrology and Dialysis Unit, AUSL Romagna Infermi Hospital, 47923 Rimini, Italy;

[3] Nephrology and Dialysis Unit, AUSL Romagna Morgagni-Pierantoni Hospital, 47121 Forlì, Italy;

[4] Nephrology and Dialysis Unit, AUSL Romagna S. Maria delle Croci Hospital, 48121 Ravenna, Italy;

[5] Nephrology, Dialysis and Renal Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy;

[6] Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy;

关键词: antibody persistence;    COVID-19;    humoral immune response;    immunodepressed patients;    renal transplant recipients;    neutralizing antibodies;   

DOI  :  10.3390/pathogens10101289

来源: DOAJ

【 摘 要 】

Nephropathic subjects with impaired immune responses show dramatically high infection rates of coronavirus disease 2019 (COVID-19). This work evaluated the ability to acquire and maintain protective antibodies over time in 26 hemodialysis patients and 21 kidney transplant recipients. The subjects were followed-up through quantitative determination of circulating SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month period after clinical and laboratory recovery. A group of 143 healthcare workers with no underlying chronic pathologies or renal diseases recovered from COVID was also evaluated. In both dialysis and transplanted patients, antibody titers reached a zenith around the 3rd month, and then a decline occurred on average between the 270th and 300th day. Immunocompromised patients who lost antibodies around the 6th month were more common than non-renal subjects, although the difference was not significant (38.5% vs. 26.6%). Considering the decay of antibody levels below the positivity threshold (15 AU/mL) as “failure”, a progressive loss of immunisation was found in the overall population starting 6 months after recovery. A longer overall antibody persistence was observed in severe forms of COVID-19 (p = 0.0183), but within each group, given the small number of patients, the difference was not significant (dialysis: p = 0.0702; transplant: p = 0.1899). These data suggest that immunocompromised renal patients recovered from COVID-19 have weakened and heterogeneous humoral responses that tend to decay over time. Despite interindividual variability, an association emerged between antibody persistence and clinical severity, similar to the subjects with preserved immune function.

【 授权许可】

Unknown